Earticle

초록

영어

Background: Helicobacter pylori (H. pylori) is a significant risk factor for gastric cancer (GC), and proton pump inhibitors (PPIs) are commonly used as part of H. pylori eradication regimens. This study aims to systematically synthesize existing evidence on the efficacy and risks of PPI use in GC prevention. Methods: Individual studies were extracted from relevant systematic reviews published between 2020 and 2024, identified through searches in PubMed, Embase, and Web of Science, and an updated search was conducted to include original articles published between 2022 and August 2025. A random-effects model was used to estimate the overall effect size of PPI-containing regimens compared to non-PPI regimens. A network meta-analysis was conducted to compare the efficacy and risks among various PPIs. Results: Total of 60 original studies were included in the final analysis. Meta-analysis showed that H. pylori eradication was associated with a 43% reduction in GC (pooled OR/HR=0.57, 95% CI=0.49-0.66). In network meta-analysis, triple therapies with lansoprazole and esomeprazole exhibited the highest treatment efficacy. In contrast, overall PPI use was associated with a 62% increased risk of gastric cancer GC (pooled OR/HR=1.62, 95% CI=1.13-2.31), particularly with long-term use. In treatment ranking, overall PPI use ranked less favorably; however, among individual regimens, lansoprazole appeared to show comparatively lower gastric cancer risk relative to other PPIs. Conclusions: This study highlights the importance of careful selection of PPI regimens, particularly those based on lansoprazole, for H. pylori eradication and GC prevention, while also considering the potential risks associated with prolonged PPI use.

목차

ABSTRACT
Method
Study protocol registration
Search strategy
Eligibility criteria
Data extraction and study quality evaluation
Statistical analysis
Results
Literature search and study flowchart
Study characteristics
Study quality evaluation
Efficacy of PPI-containing regimens in GC risk reduction
GC risk associated with PPI use
Discussion
Conflict of Interest
Author Contributions
Data Availability
Ethics Approval
Consent for Publication
Funding
References

키워드

저자

• 응오미티엔터 [ Tho My Thien Ngo | 베트남국가대학교 호치민시 보건과학대학교 약학부 ]
• 응오티지에우투이 [ Thuy Thi Dieu Ngo | 베트남국가대학교 호치민시 보건과학대학교 약학부 ]
• 부홍탕 [ Thang Hong Vu | 페니카대학교, 페니카대학교병원 암센터 ]
• 쩡마이번 [ Van Mai Truong | 베트남국가대학교 호치민시 보건과학대학교 치의·구강학부 ]
• 쩐티아인터 [ Tho Thi Anh Tran | 응에안 종양병원 소화기·간담췌내과, 하노이의학대학교 종양학과 ]
• 김정선 [ Jeongseon Kim | 국립암센터 국제암대학원대학교 의생명과학과 ]
• 황퉁 [ Tung Hoang | 베트남국가대학교 호치민시 보건과학대학교 약학부 ] Corresponding Author

참고문헌

발행기관

간행물

표지보기 관심저널 등록

• 간행물명

  한국임상약학회지 [Korean Journal of Clinical Pharmacy]

• 간기

  계간

• pISSN

  1226-6051

• 수록기간

  1991~2026

• 등재여부

  KCI 등재

• 십진분류

  KDC 518 DDC 615